StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS – Free Report) in a research report report ...

Fresenius Medical Care AG & Co. (FMS) is a stock many investors are watching right now. FMS is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ...

Third Quarter 2024 Results Key Financial Results Revenue: €5.37b (up 3.5% from 3Q ...

The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at ...

In a report released today, Graham Doyle from UBS maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (0H9X – Research ...

Deutsche Bank raised the firm’s price target on Fresenius SE (FSNUY) to EUR 44 from EUR 42 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for real-time, ...

Drug shortages in the U.S. are increasing in number and duration, primarily affecting generic and multi-sourced drugs that ...

Fresenius Medical Care AG (FMS) reports improved operating income margins and significant savings, despite challenges in the ...

Fresenius Medical Care (NYSE:FMS – Get Free Report) will be announcing its earnings results before the market opens on ...

The honor was give to Fontanez, along with his 19-year-old son Lucas and 16-year-old daughter Sydney, by the global health ...

Fresenius SE & Co. KGaA (FRE.DE) 报告了2024年第三季度的强劲业绩，有机收入增长9%，达到53亿欧元。这一增长主要由公司的Kabi和Helios部门推动。

Fresenius SE FRE0.18%increase; green up pointing triangle raised its full-year guidance after a strong third quarter driven by Kabi and good organic growth at Helios. The German healthcare company ...